Drugs / Metformin glycinate
last change Jan 2018 re-read 2 minutes ago

Metformin glycinate

Developed for
type 2 diabetes mellitus
Investigated by
Laboratorios Silanes S.A. de C.V.

Trials 4 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00960882 Jun 2007 → Mar 2008 Laboratorios Silanes S.A. de C.V. Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00940797 Jul 2008 → Feb 2009 type 2 diabetes mellitus Laboratorios Silanes S.A. de C.V. Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT00940472 Mar → Dec 2009 type 2 diabetes mellitus Laboratorios Silanes S.A. de C.V. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT01386671 Jun 2014 → Feb 2016 type 2 diabetes mellitus Laboratorios Silanes S.A. de C.V. Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Metformin glycinate “AIM: This study evaluated the effect of metformin glycinate on glycated hemoglobin A1c (A1C) concentration and insulin sensitivity in drug-naive adult patients with type 2...” PMID 22974412 Sep 2012
1

NCT01386671

Known as DMMET-01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00940472
1

NCT00960882

Known as Glicinato de metformina ChEMBL registry synonym — accepted as the source's own label CHEMBL2108299
Known as Glycinate de metformine ChEMBL registry synonym — accepted as the source's own label CHEMBL2108299
Modality Small molecule “Metformin glycinate is a new biguanide” NCT01386671